Clinical, demographic, and phenotypic characteristics and management of patients with recurrent pericarditis in real-world practice. Results of the retrospective branch of the international RUDRA registry

G. P. Arutyunov, Ekaterina Iosifovna Tarlovskaya, Д. С. Евдокимов, R. A. Bashkinov, A. Yu. Vaskin, Реснянская Екатерина Денисовна, Elizaveta Gordeychuk, A. N. Ermilova, Евгений Сергеевич Мельников, M. A. Trubnikova

26 more authors

Т. И. Батлук, A. S. Baranova, D. N. Belozerova, I. A. Vdovenko, Наталья Юрьевна Григорьева, E. I. Zheleznyak, Жданкина Наталья Викторовна, A. A. Karasev, Е. А. Карташова, Кирищева Эльза Камилевна, Ковалевская Елена Анатольевна, С. К. Кононов, O. L. Lyakhovich, S.V. Nemirova, Diana Sergeyevna Novikova, Kristina Gennadievna Pereverzeva, Н. Г. Потешкина, R. M. Rabinovich, Akhmetzhan Sugraliyev, L. K. Tkhatl, Е. В. Филиппов, Ya. B. Khovaeva, Galina Vladimirovna Shavkuta, Tatyana Viktorovna Shnyukova, Яшина Елена Михайловна, A. G. Arutyunov

Data confidence 70 medium

How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Aim . To identify the clinical and demographic profile, disease course, and management of patients with recurrent pericarditis (RP) based on data from the retrospective branch of the RUDRA registry, and to analyze specific patient subgroups. Material and methods . RUDRA (ClinicalTrials.gov: NCT06517966) is an international, multicenter, non-interventional real-world practice registry organized by the Eurasian Association of Internal Medicine, involving 20 centers across 14 regions of the Russian Federation and the Republic of Kazakhstan. The retrospective cohort included men and women aged 18 years and older with a verified diagnosis of RP established within the previous 10 years. Patient enrollment was conducted from September 30, 2024, to July 31, 2025. Statistical data analysis was performed using IBM SPSS Statistics 25. Results. The retrospective branch of the RUDRA registry included 120 patients. Idiopathic recurrent pericarditis (IRP) was verified in 33,3% (n=40), while RP of established etiology was identified in 66,7% (n=80). The median age was 63,0 [50,0;73,0] years; 55,0% were female. Patients with IRP were characterized by a significantly larger volume of pericardial effusion (386 [200;600] vs 200 [100;500] ml; p=0,008), a higher frequency of pericardial strands, clots, and adhesions (40,0% vs 11,4%; p=0,002), as well as higher rates of hospitalization (43,8% vs 9,1%; p<0,001) and disability duration (41,5 [24,2;45,8] vs 0 [0;18,5] days; p=0,024). Regarding anti-inflammatory therapy for RP, colchicine was used in 35,3% of cases overall, being significantly more frequent in the IRP group (70,0% vs 17,1%; p<0,001). Systemic glucocorticoids were prescribed to 28,4% of patients. Interleukin-1 inhibitors were received by only 2,6% of patients. Conclusion . The retrospective branch of the RUDRA registry has provided the first systematized data on real-world clinical practice in the management of patients with RP in the Russian Federation and the Republic of Kazakhstan. IRP was characterized by a more severe clinical course, a higher social burden, and predominantly medication-induced remission. A significant gap between clinical guidelines and real-world practice was identified, specifically regarding the insufficient use of colchicine in RP of known etiology and the critically low availability of interleukin-1 inhibitors.